You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
瑞康醫藥(002589.SZ):與阿斯利康共同簽署戰略合作備忘錄
格隆匯 10-19 19:34

格隆匯 10 月 19日丨瑞康醫藥(002589.SZ)公佈,20201019日,公司與阿斯利康投資(中國)有限公司(“阿斯利康”)共同簽署了《戰略合作備忘錄》。

雙方在原有的基礎上進行更密切深入的全方位戰略合作瑞康醫藥攜手阿斯利康在山東區域項目的全面落地積極參與山東144個區縣內百縣百院醫聯體的建設瑞康醫藥協助阿斯利康進行醫院准入工作

瑞康醫藥阿斯利康攜手全國範圍內拓展阿斯利康產品瑞康醫藥利用自身已建立的醫藥配送平台優勢,協助阿斯利康產品全面提升銷售能力並加大終端市場開發力度。阿斯利康在全國各分子公司的配送權方面給予瑞康醫藥支斯利康整合優勢產品資源,優先考慮瑞康醫藥瑞康醫藥在全國各分子公司的配阿斯利康願意在新產品上市後優先考慮選擇瑞康醫藥作為山東省及其他區域的配送商

醫藥阿斯利康在終端市場的拓展廣度及輻射深度方面互為發展藉助推廣飛鷹項目在山東省深度合作的良好經驗,逐步擴大其它省份的合作

瑞康醫藥積極參與阿斯利康診療一體化方案的設計和建設,為其提供藥品、器械及相關產品或技術的配套支持動態血糖監測儀等產品在診療一體化方案設計、終端拓展合作等方面開展合作成為阿斯利康診療一體化方案的一部分。雙方計劃在山東省複製無錫阿斯利康商業創新中心模式和物聯網創新等模式,將診療一體化項目在山東深入覆蓋。備忘錄自簽訂之日起五年內有效。

阿斯利康與瑞康醫藥將在“診療一體化”、醫聯體建設創新中心模式和聯網領域開展戰略合作,充分發揮各自優勢,實現雙方在醫療綜合服務領域的合作共贏的局面。如果本協議的條款充分履行將對公司未來的經營業績產生積極影響,符合公司全體股東的利益。具體影響將視項目實施情況而定。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account